Theme: Harnessing the Global Innovations in vaccines, Therapeutics and Healthcare for the better future



With the overwhelming success of previous annual Vaccines conferences, OMICS International welcomes you to attend the 8th Indo Global Summit and Expo on Vaccines, Therapeutics and Healthcare during November 2-4, 2015 in Hyderabad, India.

This conference will be the latest in a series of successful annual vaccine, Healthcare meetings organized by the OMICS International that seek to bring together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. In association with the Vaccines & Vaccination OMICS meeting there will be opportunities for those selected to present at the meeting to also publish a manuscript from their talk in the Journal of Vaccines and Vaccination or its sister publication Immunome Research.


Keynote Presentation: 
Marie-Paule Kieny, Assistant Director-General, Health Systems and Innovation
World Health Organization (WHO), USA

The attending delegates include Editorial Board Members of featured refereed Journals, Universities, Institutes and other Private Organizations to interact with the World class Scientists and renowned speakers.

The scientific sessions of the Vaccines & Vaccination conference housing all the current research in vaccines & vaccination research. Polio Vaccine will focus regarding free polio vaccine world; Cancer Vaccine will focus on translating cancer biology research into novel oncology treatments. Cancer imaging; HIV/AIDS Vaccine Human clinical trial of SAV001 prophylactic HIV vaccine and a new strategy for the development of therapeutic HIV vaccine: HPV Vaccines HPV Testing in Histological Specimens; Biodefense Vaccine, Therapeutic Vaccine and more other related topics discussed in this prestigious scientific meeting. This forum enables a common platform for the participants to discuss their research in order to establish a scientific network between the academia and industry leads to foster collaboration and to evaluate the emerging issues, technologies and innovations leads to explore new possibilities and improving the existed opportunities.

OMICS International  Vaccines 2014 Scientific Conference is sponsored by Sanofi Pasteur, France; GenPhar Inc., USA and Vaccinogen Inc., USA. With the support of Local Organizing Committee and International Organizing Committee more than 600 participants from all over the world.

Experts outlook on our previous conferences

  •  Mahesh Mohan, Tulane University Health Science Center, USA

"I enjoyed attending the vaccines business meeting and also had the opportunity to meet other researchers and learn about their research for future collaborations. The talks were informative and I had the opportunity to learn new information. Overall, I enjoyed the conference."

  • Martin D'Souza, Mercer University, USA

"Many thanks as well for organizing this very focused meetings on vaccines" 

  •   De-Chu Christopher, International Vaccine Institute, Korea

"Many thanks for organizing this great forum for brain storms to occur nonstop"

  •  Donald E. Greydanus, Western Michigan University School of Medicine, USA

"Thank you and I enjoyed the vaccines conference as well as the chance to meet with Dr. Gedela Babu to discuss various issues. I wish you continued success with your conferences"

  •  Hyunah Lee, Sungkyunkwan University School of Medicine, Korea

It was my great pleasure attending and presenting my paper at the Vaccines-2012. I am sure that the conference was successful. And your hospitality left me with deep impression"

For more relavant conferences, visit:

Scientific Sessions

Vaccine Safety: 

Vaccines are some of the safest medical products available, but like any other medical product, there may be risks. Vaccines must be safe for use by as many people as possible, vaccines are developed in accordance with the highest standards of safety. World Health Organization agree that vaccines are even safer than vitamins. Each vaccine's safety is continually monitored, even after it's been introduced. Vaccines are the best defense we have against serious, preventable, and sometimes deadly contagious diseases. Through  vaccine safety monitoring, we also make sure new vaccines are safe for people who are at high risk of complications if they get a disease, such as the elderly, those with chronic medical conditions, and pregnant women. Vaccine safety system ensures that vaccines are as safe as possible. The Food and Drug Administration (FDA) ensures the safety, effectiveness, and availability of U.S.-approved vaccines.

Child/pediatric vaccines and vaccination:

Vaccines not only help keep your child healthy, they help all children by stamping out serious childhood diseases. Immunizations have had an enormous impact on improving the health of children. It is important that we continue to protect our children with vaccines because outbreaks of vaccine-preventable diseases can and do occasionally occur in all over the world .Vaccination is one of the best ways parents can protect infants, children, and teens from 16 potentially harmful diseases. Vaccine-preventable diseases can be very serious, may require hospitalization, or even be deadly – especially in infants and young children.

Over 80% of the world's children are now being immunized against the polio virus, and the annual number of cases has been cut from 400,000 in 1980 to 90,000 in the mid-1990s. If the year 2000 goal of eradicating polio is achieved, the United States will be able to save the $270 million a year that is currently spent on polio vaccination. The savings for Western European countries will amount to about $200 million a year.

Human Vaccines-Infectiuos Diseases:

Increase immunization rates and reduce preventable infectious diseases. The increase in life expectancy during the 20th century is largely due to improvements in child survival; this increase is associated with reductions in infectious disease mortality, due largely to immunization. However, infectious diseases remain a major cause of illness, disability, and death. Immunization recommendations in the United States currently target 17 vaccine-preventable diseases across the lifespan.

Healthy People 2020 goals for immunization and infectious diseases are rooted in evidence-based clinical and community activities and services for the prevention and treatment of infectious diseases. Objectives new to Healthy People 2020 focus on technological advancements and ensuring that States, local public health departments, and nongovernmental organizations are strong partners in the Nation’s attempt to control the spread of infectious diseases. Objectives for 2020 reflect a more mobile society and the fact that diseases do not stop at geopolitical borders. Awareness of disease and completing prevention and treatment courses remain essential components for reducing infectious disease transmission.

Veterinary Vaccines: 

Veterinary vaccines are produced for administration to domestic animals or wild species by parenteral or oral routes according to vaccine characteristics. veterinary rabies vaccine has been developed using recombinant technology. Depending upon the expression system these vaccines are used either parenterally or orally. Oral rabies vaccines are widely used in foxes in Europe and in racoons in the USA. Trials are under way for the oral immunization of dogs in developing countries. Veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. Veterinary vaccines comprise only approximately 23% of the global market for animal health products, the sector has grown consistently due mainly to new technological advances in vaccine development, the continuous development of drug resistance by pathogens, and the emergence of new diseases.

For more details on the scientific sesisons follow:

Asia is emerging as the vaccine hub of the world and India is on the go to play a key role in the vaccine market. The Global vaccine market is expected to reach $10 billion during the current year 2011. This is forecasted to scale up to $23.8 Billion by the year 2012 and to reach $40 billion by the year 2015. A sharp increase in sales is expected in areas of Influenza and Hepatitis vaccines. The vaccines for cancer are expected to have a phenomenal growth due to increased disease incidence in the areas of cervical, prostrate and lung cancer. Though the pediatric vaccines were dominating the vaccine market in the past, a change in this trend is expected due to a high demand forecasted for the adult vaccines. Global adult vaccine market was around $3.7 billion during 2005 and this market is estimated to reach $7.5 billion in 2012. The major contributors to the growth of the adult vaccine market would be Influenza vaccines, HIV vaccines and Cancer Vaccines. Cancer vaccines will also become a major player in the vaccine market, rising from its current level of $135 million to more than $8 billion by 2012.

Anticipating a sizable shift in India's vaccine industry landscape, a new report estimates that the country's vaccine production sector will likely expand to an estimated $871 million by 2016. Compare that with 2011's value of $350 million.

Global Business Intelligence Research forecasts the Indian vaccine market will grow 20% a year for the next four years. New research into cancer vaccines and fears of bioterrorism and severe acute respiratory syndrome (SARS) are sparking the rise in production.

In recent years, India has emerged as a major vaccine producer, aiming efforts on geographical regions where vaccines are not funded by the United Nations or charitable organizations. Such a focus meant exports made up 65% of the Indian vaccines market last year.


"Vaccines India-2015 Organizing Committee" congratulates our previous conference best poster award winners and Young Researcher Award winners. 

4th International Conference on Vaccines & Vaccination, September 24-26, 2014 Valencia, Spain

  • Rong Xu, Cardiff University, UK

Title: IL-34 suppresses Candida albicans induced TNF-α production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression

  • Daisy Vanrompay, Ghent University, Belgium

          Title: Protection of chickens against Chlamydia psittaci challenge by  mucosal immunization with the major outer membrane protein

  • Silvia Vendetti, Istituto Superiore di Sanita, Italy

          Title: Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic boosting in mice

Welcome Message:
8th Indo Global summit and Expo on
Vaccines, Therapeutics & Healthcare (VTH-2015)


Prevention is better than cure. Vaccine comes earlier than the anticipated disease. Use to ensure better health. This ensures better coverage against disease. If fail to prevent, ensure much reduced disease impact. 

The protection needs right from birth to one is ready to go to grave. The mother protects the developing child when developing and for a limited period post birth and then the preventive vaccine starts the magic of protecting you from the ill effects from the common disease(s).

It is no longer belief that children only need protection. Any age any time, we all need protection from the infectious diseases. The phrase “WOMB TO TOMB” justifies the various protective vaccines all over spread life.

I feel very happy that the “World Vaccine Congress 2015” will add more information, better understanding, and healthier human health. Infection is not the problem of any one country but is for all. All nations must join hands with the International Health Agencies to deal the problem together. We should stand firm as “United World for Health”.

With best wishes for a very successful Congress.


Dr. (Professor) A K Prasad,
Former University Prof & HOD,
Respiratory Virology, V.Patel Chest Institute, Delhi,
Medical Microbiology, Delhi University.
Chairman, Influenza Foundation of India,

President, Biotechnology Society of India,

Former President, Indian College of  Allergy & Applied Immunology.
Former Editor, Indian J. of Allergy & Applied Immunology.Former Short-time Consultant WHO (SEARO) Delhi.

Member Asia Pacific Alliance for the Control of Influenza (APACI) Ltd.

President, Indian Virological Society. ( in process of renaming as ACADEMY OF VIROLOGIST)

Executive Council Member, Ind. College of Asthma, Allergy & Immunology

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date November 02-04, 2015
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2 Day 3
Poster Opportunity Closed Click Here to View